Ribociclib (Kisqali) as part of subsequent hormone therapy for advanced breast cancer in women after menopause
In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) last looked into the advantages and disadvantages of ribociclib (Kisqali) when used as part of subsequent hormone therapy for advanced hormone-receptor-positive and HER2-negative breast cancer in women after menopause when compared with the standard treatments. Ribociclib was assessed in combination with fulvestrant.
The manufacturer provided one study comparing the combination of ribociclib and fulvestrant with the standard treatment fulvestrant in combination with a placebo (fake treatment).
The data of a total of 139 women was analyzed for this assessment. 100 of these participants had treatment with ribociclib and fulvestrant, and the remaining 39 were given fulvestrant with a placebo. This is what was found: